- Home
- BCG vs ALVR Comparison
BCG vs ALVR Comparison
Compare BCG & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- ALVR
- Stock Information
- Founded
- BCG 2016
- ALVR 2013
- Country
- BCG United States
- ALVR United States
- Employees
- BCG N/A
- ALVR N/A
- Industry
- BCG
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCG
- ALVR Health Care
- Exchange
- BCG Nasdaq
- ALVR Nasdaq
- Market Cap
- BCG 42.3M
- ALVR 48.8M
- IPO Year
- BCG N/A
- ALVR 2020
- Fundamental
- Price
- BCG $1.90
- ALVR $9.63
- Analyst Decision
- BCG
- ALVR
- Analyst Count
- BCG 0
- ALVR 0
- Target Price
- BCG N/A
- ALVR N/A
- AVG Volume (30 Days)
- BCG 40.4K
- ALVR 22.4K
- Earning Date
- BCG 03-03-2025
- ALVR 03-14-2025
- Dividend Yield
- BCG N/A
- ALVR N/A
- EPS Growth
- BCG N/A
- ALVR N/A
- EPS
- BCG N/A
- ALVR N/A
- Revenue
- BCG $161,721,000.00
- ALVR N/A
- Revenue This Year
- BCG N/A
- ALVR N/A
- Revenue Next Year
- BCG N/A
- ALVR N/A
- P/E Ratio
- BCG N/A
- ALVR N/A
- Revenue Growth
- BCG N/A
- ALVR N/A
- 52 Week Low
- BCG $1.81
- ALVR $7.96
- 52 Week High
- BCG $16.61
- ALVR $24.15
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- ALVR 45.63
- Support Level
- BCG N/A
- ALVR $9.55
- Resistance Level
- BCG N/A
- ALVR $10.41
- Average True Range (ATR)
- BCG 0.00
- ALVR 0.44
- MACD
- BCG 0.00
- ALVR 0.05
- Stochastic Oscillator
- BCG 0.00
- ALVR 22.77
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.